Mesoblast Limited (MEOBF)
OTCMKTS · Delayed Price · Currency is USD
0.9650
0.00 (0.00%)
At close: Jun 23, 2025
Mesoblast Employees
Mesoblast had 73 employees as of June 30, 2024. The number of employees decreased by 10 or -12.05% compared to the previous year.
Employees
73
Change (1Y)
-10
Growth (1Y)
-12.05%
Revenue / Employee
$77,671
Profits / Employee
-$1,415,767
Market Cap
1.93B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Endo, Inc. | 3,116 |
Tian'an Technology Group | 8 |
Elite Pharmaceuticals | 68 |
Glass House Brands | 374 |
CytoDyn | 9 |
Northwest Biotherapeutics | 25 |
American Oncology Network | 1,914 |
Silence Therapeutics | 116 |
Mesoblast News
- 4 days ago - Mesoblast shares soar 35pc on strong cell therapy sales data - The Australian Financial Review
- 4 days ago - Successful Commercial Launch of Ryoncil® - Benzinga
- 4 days ago - Successful Commercial Launch of Ryoncil® - GlobeNewsWire
- 4 days ago - ASX 200 LIVE: ASX 200 at record; Mesoblast soars 30pc on sales boost - The Australian Financial Review
- 14 days ago - Mesoblast: A Cautionary Hold On Regenerative Medicine's Risky Edge (Upgrade) - Seeking Alpha
- 20 days ago - Mesoblast, Atai Life Sciences, Melco Resorts & Entertainment And Other Big Stocks Moving Higher On Tuesday - Benzinga
- 20 days ago - Mesoblast, FDA agree on marketing application for cell therapy - Seeking Alpha
- 20 days ago - Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor - Benzinga